Granules India Completes Acquisition of Senn Chemicals
11 Apr 2025
2 Min Read
CW Team
Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules鈥� entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy.
The acquisition, executed through Granules鈥� wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family.
Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets.
Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a 鈥減ivotal step鈥� in the company鈥檚 evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn鈥檚 peptide specialisation and Granules鈥� global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies.
The acquisition also marks Granules鈥� formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works.
Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation).
This acquisition strengthens Granules鈥� innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets.
(BSE)
Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules鈥� entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. The acquisition, executed through Granules鈥� wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a 鈥減ivotal step鈥� in the company鈥檚 evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn鈥檚 peptide specialisation and Granules鈥� global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. The acquisition also marks Granules鈥� formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). This acquisition strengthens Granules鈥� innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. (BSE)
Next Story
Mumbai-Ahmedabad Bullet Train Set to Launch by 2028
India鈥檚 first bullet train is set to revolutionize high-speed travel along the western corridor, with the Mumbai-Ahmedabad high-speed rail project aiming for a 2028 launch. This announcement marks a major milestone in India鈥檚 infrastructure goals, as it promises to reduce travel time between the two economic hubs from eight hours to just three.Spanning a planned 508-kilometre stretch, the corridor stands as a flagship example of Indo-Japanese collaboration in technology and engineering. Once operational, the train is expected to transform intercity mobility and place India among the select..
Next Story
Mumbai-Gandhinagar Train Service Enhances Passenger Capacity
The Mumbai Central鈥揋andhinagar Capital Vande Bharat Express has increased its passenger capacity by adding four additional AC chair car coaches to meet the growing commuter demand on one of India鈥檚 busiest business corridors. This upgrade, effective from 11 May, raised the train鈥檚 seating capacity from 1,128 to 1,440 passengers, allowing it to serve 936 more passengers daily in both directions. The increase was described as a practical measure to accommodate the surging demand on the busy Mumbai鈥揂hmedabad鈥揋andhinagar route, which regularly operates at over 150 percent seat occupancy...
Next Story
Delhi Plans 12 Sewage Plants to Clean Najafgarh Drain Efficiently
Delhi鈥檚 ambitious plan to improve the water quality of the Yamuna River has gained significant momentum as the Delhi Jal Board (DJB) has begun work on 12 new sewage treatment plants (STPs) aimed at reducing the volume of untreated sewage being discharged from the Najafgarh Drain.This initiative forms part of the ongoing efforts to clean the Yamuna and restore the river鈥檚 health, which has long been a critical environmental issue for the national capital. Given the alarming pollution levels in the Yamuna, experts and officials consider this project a vital step toward addressing the persist..
